1 results match your criteria: "Stephenson Cancer Center at the University of Oklahoma HSC Oklahoma City[Affiliation]"
Olaparib in the treatment of ovarian cancer.
Future Oncol
October 2019
Division of Gynecologic Oncology, Stephenson Cancer Center at the University of Oklahoma HSC Oklahoma City, OK 73121, USA.
The poly ADP ribose polymerase olaparib is currently approved in front line -associated epithelial ovarian cancer (EOC), platinum-sensitive recurrence agnostic to BRCA status and for gBRCA as treatment in the fourth line and beyond. Women who are diagnosed with advanced stage EOC face a formidable challenge in overcoming their disease and achieving long-term, disease-free survival. The qualifier here is disease free.
View Article and Find Full Text PDF